Home › Funds › PERCEPTIVE ADVISORS LLC › RYTM

PERCEPTIVE ADVISORS LLC position in RYTM

RHYTHM PHARMACEUTICALS INC · Health Care

PERCEPTIVE ADVISORS LLC reported holding 2,586,295 shares of RYTM (RHYTHM PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$287.2M, representing 4.56% of its reported portfolio and ranking #4 among its reported holdings. PERCEPTIVE ADVISORS LLC has disclosed RYTM holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)2.59M sh
Reported value held$287.16M
Portfolio Weight4.56%
First reportedQ3 2023
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How PERCEPTIVE ADVISORS LLC's RYTM position evolved

PERCEPTIVE ADVISORS LLC first disclosed a stake in RYTM in Q3 2023 at 380,828 shares (US$8.7M). The position peaked in Q3 2025 at 419,104,969 shares, worth US$288.4M. Across 12 filings, PERCEPTIVE ADVISORS LLC increased the stake 7 time(s), trimmed it 4 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 2,586,295 shares valued at US$287.2M — an increase of 212,500 shares quarter over quarter.. Notable position changes include a 466% increase in Q4 2023 (shares fell 6% over the following quarter), a 17231% increase in Q3 2025 (shares rose 6% over the following quarter), a 99% trim in Q4 2025 (shares fell 19% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 380.83K $8.73M New
Q4 2023 2.15M $99.02M Add
Q1 2024 3.27M $141.63M Add
Q2 2024 3.45M $141.52M Add
Q3 2024 3.56M $186.52M Add
Q4 2024 3.68M $206.03M Add
Q1 2025 2.55M $134.99M Reduce
Q2 2025 2.42M $152.81M Reduce
Q3 2025 419.10M $288.39M Add
Q4 2025 2.55M $272.57M Reduce
Q1 2026 2.37M $206.45M Reduce
Q2 2026 2.59M $287.16M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About RYTM and 13F data

RYTM (RHYTHM PHARMACEUTICALS INC) is a Health Care company. 51 other funds we track also report a position in RYTM — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$740.2M), BAKER BROS. ADVISORS LP (US$622.3M), WESTFIELD CAPITAL MANAGEMENT CO LP (US$245.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding RYTM

All RYTM fund holders →

FAQ

How long has PERCEPTIVE ADVISORS LLC held RYTM?

PERCEPTIVE ADVISORS LLC has disclosed RYTM holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is PERCEPTIVE ADVISORS LLC's current position in RYTM?

As of Q2 2026, PERCEPTIVE ADVISORS LLC holds 2.59M shares of RYTM (RHYTHM PHARMACEUTICALS INC), valued at $287.16M, representing 4.56% of its reported portfolio and ranking #4.

Has PERCEPTIVE ADVISORS LLC been buying or selling RYTM?

In the latest 13F filing (Q2 2026), PERCEPTIVE ADVISORS LLC increased its position in RYTM. The position peaked in Q3 2025 at 419.10M shares.

Which other funds hold RYTM?

Other major institutional holders of RYTM include RA CAPITAL MANAGEMENT, L.P., BAKER BROS. ADVISORS LP, WESTFIELD CAPITAL MANAGEMENT CO LP, among 51 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.